Free Trial

Centessa Pharmaceuticals Q4 2023 Earnings Report

Centessa Pharmaceuticals logo
$13.16 -1.22 (-8.45%)
As of 03:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Centessa Pharmaceuticals EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.44
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Centessa Pharmaceuticals Revenue Results

Actual Revenue
$6.85 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Centessa Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A
Remove Ads

Centessa Pharmaceuticals Earnings Headlines

B. Riley Equities Analysts Cut Earnings Estimates for CNTA
A market crash is coming—here’s when
The stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.
Centessa reports Q4 EPS (84c), consensus (35c)
See More Centessa Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Centessa Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Centessa Pharmaceuticals and other key companies, straight to your email.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals (NASDAQ:CNTA), a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

View Centessa Pharmaceuticals Profile

More Earnings Resources from MarketBeat